Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Ovarian tumours of different histologic type and clinical stage induce similar changes in lipid metabolism.

Niemi RJ, Braicu EI, Kulbe H, Koistinen KM, Sehouli J, Puistola U, Mäenpää JU, Hilvo M.

Br J Cancer. 2018 Oct;119(7):847-854. doi: 10.1038/s41416-018-0270-z. Epub 2018 Oct 8.

PMID:
30293997
2.

APOBEC3B protein expression and mRNA analyses in patients with high-grade serous ovarian carcinoma.

Rüder U, Denkert C, Kunze CA, Jank P, Lindner J, Jöhrens K, Kulbe H, Sehouli J, Dietel M, Braicu E, Darb-Esfahani S.

Histol Histopathol. 2018 Oct 5:18050. doi: 10.14670/HH-18-050. [Epub ahead of print]

PMID:
30289149
3.

Morphology and tumour-infiltrating lymphocytes in high-stage, high-grade serous ovarian carcinoma correlated with long-term survival.

Darb-Esfahani S, Kolaschinski I, Trillsch F, Mahner S, Concin N, Vergote I, Van Nieuwenhuysen E, Achimas-Cadariu P, Glajzer J, Woopen H, Wienert S, Taube ET, Stanske M, Kulbe H, Denkert C, Sehouli J, Braicu EI.

Histopathology. 2018 Jul 14. doi: 10.1111/his.13711. [Epub ahead of print]

PMID:
30007074
4.

Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study).

Ruscito I, Cacsire Castillo-Tong D, Vergote I, Ignat I, Stanske M, Vanderstichele A, Glajzer J, Kulbe H, Trillsch F, Mustea A, Kreuzinger C, Benedetti Panici P, Gourley C, Gabra H, Nuti M, Taube ET, Kessler M, Sehouli J, Darb-Esfahani S, Braicu EI.

Br J Cancer. 2018 Aug;119(3):330-338. doi: 10.1038/s41416-018-0157-z. Epub 2018 Jun 29.

PMID:
29955134
5.

The prognostic impact of cancer stem-like cell biomarker aldehyde dehydrogenase-1 (ALDH1) in ovarian cancer: A meta-analysis.

Ruscito I, Darb-Esfahani S, Kulbe H, Bellati F, Zizzari IG, Rahimi Koshkaki H, Napoletano C, Caserta D, Rughetti A, Kessler M, Sehouli J, Nuti M, Braicu EI.

Gynecol Oncol. 2018 Jul;150(1):151-157. doi: 10.1016/j.ygyno.2018.05.006. Epub 2018 May 10.

PMID:
29753392
6.

Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer.

Stanske M, Wienert S, Castillo-Tong DC, Kreuzinger C, Vergote I, Lambrechts S, Gabra H, Gourley C, Ganapathi RN, Kolaschinski I, Budczies J, Sehouli J, Ruscito I, Denkert C, Kulbe H, Schmitt W, Jöhrens K, Braicu I, Darb-Esfahani S.

Neoplasia. 2018 Mar;20(3):280-288. doi: 10.1016/j.neo.2018.01.007. Epub 2018 Feb 22.

7.

Genetic Versus Epigenetic BRCA1 Silencing Pathways: Clinical Effects in Primary Ovarian Cancer Patients: A Study of the Tumor Bank Ovarian Cancer Consortium.

Sun T, Ruscito I, Dimitrova D, Chekerov R, Kulbe H, Baron U, Blanchard V, Panici PB, Darb-Esfahani S, Sehouli J, Olek S, Braicu EI.

Int J Gynecol Cancer. 2017 Oct;27(8):1658-1665. doi: 10.1097/IGC.0000000000001071.

PMID:
28691938
8.

Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium.

Ruscito I, Cacsire Castillo-Tong D, Vergote I, Ignat I, Stanske M, Vanderstichele A, Ganapathi RN, Glajzer J, Kulbe H, Trillsch F, Mustea A, Kreuzinger C, Benedetti Panici P, Gourley C, Gabra H, Kessler M, Sehouli J, Darb-Esfahani S, Braicu EI.

Eur J Cancer. 2017 Jul;79:214-225. doi: 10.1016/j.ejca.2017.04.016. Epub 2017 May 16.

9.

A CCR4 antagonist reverses the tumor-promoting microenvironment of renal cancer.

Berlato C, Khan MN, Schioppa T, Thompson R, Maniati E, Montfort A, Jangani M, Canosa M, Kulbe H, Hagemann UB, Duncan AR, Fletcher L, Wilkinson RW, Powles T, Quezada SA, Balkwill FR.

J Clin Invest. 2017 Mar 1;127(3):801-813. doi: 10.1172/JCI82976. Epub 2017 Jan 30.

10.

Integrated transcriptomic and proteomic analysis identifies protein kinase CK2 as a key signaling node in an inflammatory cytokine network in ovarian cancer cells.

Kulbe H, Iorio F, Chakravarty P, Milagre CS, Moore R, Thompson RG, Everitt G, Canosa M, Montoya A, Drygin D, Braicu I, Sehouli J, Saez-Rodriguez J, Cutillas PR, Balkwill FR.

Oncotarget. 2016 Mar 29;7(13):15648-61. doi: 10.18632/oncotarget.7255.

11.

Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.

Darb-Esfahani S, Kunze CA, Kulbe H, Sehouli J, Wienert S, Lindner J, Budczies J, Bockmayr M, Dietel M, Denkert C, Braicu I, Jöhrens K.

Oncotarget. 2016 Jan 12;7(2):1486-99. doi: 10.18632/oncotarget.6429.

12.

Adaptive Upregulation of EGFR Limits Attenuation of Tumor Growth by Neutralizing IL6 Antibodies, with Implications for Combined Therapy in Ovarian Cancer.

Milagre CS, Gopinathan G, Everitt G, Thompson RG, Kulbe H, Zhong H, Hollingsworth RE, Grose R, Bowtell DD, Hochhauser D, Balkwill FR.

Cancer Res. 2015 Apr 1;75(7):1255-64. doi: 10.1158/0008-5472.CAN-14-1801. Epub 2015 Feb 10.

13.

Murine CD27(-) Vγ6(+) γδ T cells producing IL-17A promote ovarian cancer growth via mobilization of protumor small peritoneal macrophages.

Rei M, Gonçalves-Sousa N, Lança T, Thompson RG, Mensurado S, Balkwill FR, Kulbe H, Pennington DJ, Silva-Santos B.

Proc Natl Acad Sci U S A. 2014 Aug 26;111(34):E3562-70. doi: 10.1073/pnas.1403424111. Epub 2014 Aug 11.

14.

Cancer cell-derived lymphotoxin mediates reciprocal tumour-stromal interactions in human ovarian cancer by inducing CXCL11 in fibroblasts.

Lau TS, Chung TK, Cheung TH, Chan LK, Cheung LW, Yim SF, Siu NS, Lo KW, Yu MM, Kulbe H, Balkwill FR, Kwong J.

J Pathol. 2014 Jan;232(1):43-56. doi: 10.1002/path.4258.

PMID:
24014111
15.

Vaccinia virus induces programmed necrosis in ovarian cancer cells.

Whilding LM, Archibald KM, Kulbe H, Balkwill FR, Öberg D, McNeish IA.

Mol Ther. 2013 Nov;21(11):2074-86. doi: 10.1038/mt.2013.195. Epub 2013 Sep 24.

16.

The role of interleukin-6 in gynaecological malignancies.

Coward JI, Kulbe H.

Cytokine Growth Factor Rev. 2012 Dec;23(6):333-42. doi: 10.1016/j.cytogfr.2012.08.005. Epub 2012 Sep 30. Review.

PMID:
23031497
17.

The peritoneal tumour microenvironment of high-grade serous ovarian cancer.

Leinster DA, Kulbe H, Everitt G, Thompson R, Perretti M, Gavins FN, Cooper D, Gould D, Ennis DP, Lockley M, McNeish IA, Nourshargh S, Balkwill FR.

J Pathol. 2012 Jun;227(2):136-45. doi: 10.1002/path.4002. Epub 2012 Apr 18.

18.

Sequential genetic change at the TP53 and chemokine receptor CXCR4 locus during transformation of human ovarian surface epithelium.

Archibald KM, Kulbe H, Kwong J, Chakravarty P, Temple J, Chaplin T, Flak MB, McNeish IA, Deen S, Brenton JD, Young BD, Balkwill F.

Oncogene. 2012 Nov 29;31(48):4987-95. doi: 10.1038/onc.2011.653. Epub 2012 Jan 23.

19.

A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment.

Kulbe H, Chakravarty P, Leinster DA, Charles KA, Kwong J, Thompson RG, Coward JI, Schioppa T, Robinson SC, Gallagher WM, Galletta L; Australian Ovarian Cancer Study Group, Salako MA, Smyth JF, Hagemann T, Brennan DJ, Bowtell DD, Balkwill FR.

Cancer Res. 2012 Jan 1;72(1):66-75. doi: 10.1158/0008-5472.CAN-11-2178. Epub 2011 Nov 7.

20.

Interleukin-6 as a therapeutic target in human ovarian cancer.

Coward J, Kulbe H, Chakravarty P, Leader D, Vassileva V, Leinster DA, Thompson R, Schioppa T, Nemeth J, Vermeulen J, Singh N, Avril N, Cummings J, Rexhepaj E, Jirström K, Gallagher WM, Brennan DJ, McNeish IA, Balkwill FR.

Clin Cancer Res. 2011 Sep 15;17(18):6083-96. doi: 10.1158/1078-0432.CCR-11-0945. Epub 2011 Jul 27.

21.

B regulatory cells and the tumor-promoting actions of TNF-α during squamous carcinogenesis.

Schioppa T, Moore R, Thompson RG, Rosser EC, Kulbe H, Nedospasov S, Mauri C, Coussens LM, Balkwill FR.

Proc Natl Acad Sci U S A. 2011 Jun 28;108(26):10662-7. doi: 10.1073/pnas.1100994108. Epub 2011 Jun 13.

22.

IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer.

Anglesio MS, George J, Kulbe H, Friedlander M, Rischin D, Lemech C, Power J, Coward J, Cowin PA, House CM, Chakravarty P, Gorringe KL, Campbell IG; Australian Ovarian Cancer Study Group, Okamoto A, Birrer MJ, Huntsman DG, de Fazio A, Kalloger SE, Balkwill F, Gilks CB, Bowtell DD.

Clin Cancer Res. 2011 Apr 15;17(8):2538-48. doi: 10.1158/1078-0432.CCR-10-3314. Epub 2011 Feb 22.

23.

Inhibition of the inflammatory cytokine TNF-α increases adenovirus activity in ovarian cancer via modulation of cIAP1/2 expression.

Salako MA, Kulbe H, Ingemarsdotter CK, Pirlo KJ, Williams SL, Lockley M, Balkwill FR, McNeish IA.

Mol Ther. 2011 Mar;19(3):490-9. doi: 10.1038/mt.2010.247. Epub 2010 Nov 16.

24.

The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans.

Charles KA, Kulbe H, Soper R, Escorcio-Correia M, Lawrence T, Schultheis A, Chakravarty P, Thompson RG, Kollias G, Smyth JF, Balkwill FR, Hagemann T.

J Clin Invest. 2009 Oct;119(10):3011-23. doi: 10.1172/JCI39065. Epub 2009 Sep 8.

25.

An antagonist of the chemokine receptor CXCR4 induces mitotic catastrophe in ovarian cancer cells.

Kwong J, Kulbe H, Wong D, Chakravarty P, Balkwill F.

Mol Cancer Ther. 2009 Jul;8(7):1893-905. doi: 10.1158/1535-7163.MCT-08-0966. Epub 2009 Jun 30.

26.

"Re-educating" tumor-associated macrophages by targeting NF-kappaB.

Hagemann T, Lawrence T, McNeish I, Charles KA, Kulbe H, Thompson RG, Robinson SC, Balkwill FR.

J Exp Med. 2008 Jun 9;205(6):1261-8. doi: 10.1084/jem.20080108. Epub 2008 May 19.

27.

Ovarian cancer cell-derived migration inhibitory factor enhances tumor growth, progression, and angiogenesis.

Hagemann T, Robinson SC, Thompson RG, Charles K, Kulbe H, Balkwill FR.

Mol Cancer Ther. 2007 Jul;6(7):1993-2002.

28.

The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells.

Kulbe H, Thompson R, Wilson JL, Robinson S, Hagemann T, Fatah R, Gould D, Ayhan A, Balkwill F.

Cancer Res. 2007 Jan 15;67(2):585-92.

29.

Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype.

Hagemann T, Wilson J, Burke F, Kulbe H, Li NF, Plüddemann A, Charles K, Gordon S, Balkwill FR.

J Immunol. 2006 Apr 15;176(8):5023-32.

30.

Expression and regulation of tumor necrosis factor alpha in normal and malignant ovarian epithelium.

Szlosarek PW, Grimshaw MJ, Kulbe H, Wilson JL, Wilbanks GD, Burke F, Balkwill FR.

Mol Cancer Ther. 2006 Feb;5(2):382-90.

31.

The inflammatory cytokine tumor necrosis factor-alpha regulates chemokine receptor expression on ovarian cancer cells.

Kulbe H, Hagemann T, Szlosarek PW, Balkwill FR, Wilson JL.

Cancer Res. 2005 Nov 15;65(22):10355-62.

32.

Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK.

Hagemann T, Wilson J, Kulbe H, Li NF, Leinster DA, Charles K, Klemm F, Pukrop T, Binder C, Balkwill FR.

J Immunol. 2005 Jul 15;175(2):1197-205.

33.

The chemokine network in cancer--much more than directing cell movement.

Kulbe H, Levinson NR, Balkwill F, Wilson JL.

Int J Dev Biol. 2004;48(5-6):489-96. Review.

34.

Mucin gene (MUC1) transfer into human dendritic cells by cationic liposomes and recombinant adenovirus.

Pecher G, Spahn G, Schirrmann T, Kulbe H, Ziegner M, Schenk JA, Sandig V.

Anticancer Res. 2001 Jul-Aug;21(4A):2591-6.

PMID:
11724326
35.

Long-term tumor growth suppression in mice immunized with naked DNA of the human tumor antigen mucin (MUC1).

Johnen H, Kulbe H, Pecher G.

Cancer Immunol Immunother. 2001 Sep;50(7):356-60.

PMID:
11676395

Supplemental Content

Support Center